{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-24-008787","form_type":"8-K","ticker":"PTGX","cik":"0001377121","company_name":"Protagonist Therapeutics, Inc","filed_at":"2024-01-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:23.995872+00:00","generated_at":"2026-06-06T13:11:41.912805+00:00","sec_items":["1.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.9,"calibrated_materiality_score":0.9,"confidence":"high","headline":"Protagonist Therapeutics signs $300M upfront collaboration with Takeda for rusfertide","bullets":["Takeda pays $300M upfront within 30 days of HSR clearance; 50/50 profit-loss share in U.S.","Tiered royalties of 10-17% in ex-US territory; up to 29% if opt-out exercised.","Milestones up to $330M (no opt-out) or up to $975M (with opt-out); plus $400M opt-out payment potential.","Takeda leads global commercialization; Protagonist holds option to co-detail in U.S.","Takeda may terminate for convenience after Phase 3 data or 3rd anniversary of effective date."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-24-008787","json":"https://secwatch.observer/filing/0001104659-24-008787.json","markdown":"https://secwatch.observer/filing/0001104659-24-008787.md","text":"https://secwatch.observer/filing/0001104659-24-008787.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924008787/0001104659-24-008787-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924008787/tm244678d1_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-06T13:11:41.912805+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"542d2c40c01e4e49a8d6a5a23043815392ccb0cb","claim":"Protagonist Therapeutics, Inc entered into License and Collaboration Agreement with Takeda Pharmaceuticals USA, Inc. valued at $300 million (effective 2024-01-31).","evidence_excerpt":"On January 31, 2024, Protagonist Therapeutics, Inc. (the “ Company ”) entered into a License and Collaboration Agreement (the “ Collaboration Agreement ”) with Takeda Pharmaceuticals USA, Inc. (“ Takeda ”) for the development, manufacture and commercialization of the Company’s rusfertide product candidate","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1377121/000110465924008787/0001104659-24-008787-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"entry"},{"label":"Agreement","value":"collaboration"},{"label":"Counterparty","value":"Takeda Pharmaceuticals USA, Inc."},{"label":"Value","value":"$300 million"},{"label":"Effective","value":"2024-01-31"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}